Innolake Biopharm

Innolake Biopharm is a clinical stage biotech company based in China, focusing on innovative therapeutics in oncology and autoimmune disease areas. Founded in 2020 by industry veterans Dr. Mingde Xia and Mr. Robert Chen, the company has made significant strides in a short time. With a $40 million Series Pre-A funding backed by WuXi, Zhongbo Juli, and Hangzhou Heda Industry Fund, Innolake emphasizes innovation as the core of its strategy. The company has a top-tier scientific and clinical development team and is committed to developing proprietary technology platforms and R&D capabilities. It has established a robust pipeline with more than ten first-in-class and best-in-class drug candidates, with two entering the clinical stage. Recently, Innolake was recognized as a “Chinese Next Unicorn” enterprise and listed on the ”2021 China Biopharmaceutical Industry Innovation Top100 List”. Innolake's vision to improve the lives of patients globally through its innovative medicines against cancer and autoimmune diseases, coupled with a strong scientific and clinical team and significant backing, positions it as a promising player in the biotech industry.